Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response.
The post Fractyl’s Weight Maintenance Device Meets Clinical Goal, but Shares Nosedive, Layoffs Follow appeared first on MedCity News.
